Cita APA

Knight, J. M., Rizzo, J. D., Hari, P., Pasquini, M. C., Giles, K. E., D’Souza, A., . . . Cole, S. W. (2020). Propranolol inhibits molecular risk markers in HCT recipients: A phase 2 randomized controlled biomarker trial. Blood Adv.

Chicago Style Citation

Knight, Jennifer M., et al. "Propranolol Inhibits Molecular Risk Markers in HCT Recipients: A Phase 2 Randomized Controlled Biomarker Trial." Blood Adv 2020.

Cita MLA

Knight, Jennifer M., et al. "Propranolol Inhibits Molecular Risk Markers in HCT Recipients: A Phase 2 Randomized Controlled Biomarker Trial." Blood Adv 2020.